PROX1 Interaction with α-SMA-rich Cancer-associated Fibroblasts Facilitates Colorectal Cancer Progression and Correlates with Poor Clinical Outcomes and Therapeutic Resistance

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2024 Jan 20

PMID 38244581

Authors

Shiue-Wei Lai

Yi-Chiao Cheng

Kee-Thai Kiu

Min-Hsuan Yen

Ying-Wei Chen

Vijesh Kumar Yadav

Chi-Tai Yeh

Kuang-Tai Kuo

Tung-Cheng Chang

Affiliations

Soon will be listed here.

Abstract

Background: The tumor microenvironment (TME) plays a vital role in tumor progression through intricate molecular interactions. Cancer-associated fibroblasts (CAFs), notably those expressing alpha-smooth muscle actin (α-SMA) or myofibroblasts, are instrumental in this context and correlate with unfavorable outcomes in colorectal cancer (CRC). While several transcription factors influence TME, the exact regulator causing CAF dysregulation in CRC remains elusive. Prospero Homeobox 1 (PROX1) stands out, as its inhibition reduces α-SMA-rich CAF activity. However, the therapeutic role of PROX1 is debated due to inconsistent study findings.

Methods: Using the ULCAN portal, we noted an elevated PROX1 level in advanced colon adenocarcinoma, linking to a poor prognosis. Assays determined the impact of PROX1 overexpression on CRC cell properties, while co-culture experiments spotlighted the PROX1-CAF relationship. Molecular expressions were validated by qRT-PCR and Western blots, with studies further solidifying the observations.

Results: Our study emphasized the connection between PROX1 and α-SMA in CAFs. Elevated PROX1 in CRC samples correlated with increased α-SMA in tumors. PROX1 modulation influenced the behavior of specific CRC cells, with its overexpression fostering invasiveness. Kaplan-Meier evaluations demonstrated a link between PROX1 or α-SMA and survival outcomes. Consequently, PROX1, alone or with α-SMA, emerges as a CRC prognostic marker. Co-culture and animal experiments further highlighted this relationship.

Conclusion: PROX1 appears crucial in modulating CRC behavior and therapeutic resistance within the TME by influencing CAFs, signifying the combined PROX1/α-SMA gene as a potential CRC prognostic marker. The concept of developing inhibitors targeting this gene set emerges as a prospective therapeutic strategy. However, this study is bound by limitations, including potential challenges in clinical translation, a focused exploration on PROX1/α-SMA potentially overlooking other significant molecular contributors, and the preliminary nature of the inhibitor development proposition.

Citing Articles

Leveraging microbiome signatures to predict tumor immune microenvironment and prognosis of patients with endometrial carcinoma.

Yang Y, Meng Y, Xu Z, Zhang Q, Li M, Kong F Discov Oncol. 2025; 16(1):299.

PMID: 40069468 PMC: 11896907. DOI: 10.1007/s12672-025-02038-9.

Exploring Label-Free Imaging Techniques with Copper Sulfide Microspheres for Observing Breast Cancer Cells.

Kadarwati L, Lin I, Huang Y, Lee Y, Chen S, Chung C ACS Omega. 2024; 9(36):37882-37890.

PMID: 39281899 PMC: 11391449. DOI: 10.1021/acsomega.4c04154.

PROX1 is a regulator of neuroendocrine-related gene expression in lung carcinoid.

Sakurai K, Ando T, Sakai Y, Mori Y, Nakamura S, Kato T Hum Cell. 2024; 37(5):1559-1566.

PMID: 39066858 DOI: 10.1007/s13577-024-01109-3.

References

Fanali C, Lucchetti D, Farina M, Corbi M, Cufino V, Cittadini A . Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives. World J Gastroenterol. 2014; 20(4):923-42. PMC: 3921545. DOI: 10.3748/wjg.v20.i4.923. View

Rodrigues M, de Oliveira Rodini C, de Aquino Xavier F, Paiva K, Severino P, Moyses R . PROX1 gene is differentially expressed in oral cancer and reduces cellular proliferation. Medicine (Baltimore). 2014; 93(28):e192. PMC: 4603077. DOI: 10.1097/MD.0000000000000192. View

Vu T, Datta P . Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis. Cancers (Basel). 2017; 9(12). PMC: 5742819. DOI: 10.3390/cancers9120171. View

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

Lee E, Yeo S, Lee K, Lee J, Kim K, Kim S . New screening system using Twist1 promoter activity identifies dihydrorotenone as a potent drug targeting cancer-associated fibroblasts. Sci Rep. 2020; 10(1):7058. PMC: 7184745. DOI: 10.1038/s41598-020-63996-4. View

Patel A, Vipparthi K, Thatikonda V, Arun I, Bhattacharjee S, Sharan R . A subtype of cancer-associated fibroblasts with lower expression of alpha-smooth muscle actin suppresses stemness through BMP4 in oral carcinoma. Oncogenesis. 2018; 7(10):78. PMC: 6172238. DOI: 10.1038/s41389-018-0087-x. View

Garcia M, Ghiani M, Lefort A, Libert F, Strollo S, Vassart G . LGR5 deficiency deregulates Wnt signaling and leads to precocious Paneth cell differentiation in the fetal intestine. Dev Biol. 2009; 331(1):58-67. DOI: 10.1016/j.ydbio.2009.04.020. View

Dzobo K, Dandara C . Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance. OMICS. 2020; 24(6):314-339. DOI: 10.1089/omi.2020.0023. View

Wiener Z, Hogstrom J, Hyvonen V, Band A, Kallio P, Holopainen T . Prox1 promotes expansion of the colorectal cancer stem cell population to fuel tumor growth and ischemia resistance. Cell Rep. 2014; 8(6):1943-1956. DOI: 10.1016/j.celrep.2014.08.034. View

10.

Shimoda M, Takahashi M, Yoshimoto T, Kono T, Ikai I, Kubo H . A homeobox protein, prox1, is involved in the differentiation, proliferation, and prognosis in hepatocellular carcinoma. Clin Cancer Res. 2006; 12(20 Pt 1):6005-11. DOI: 10.1158/1078-0432.CCR-06-0712. View

11.

Yeo S, Ha S, Lee K, Cui Y, Yang Z, Xuan Y . Twist1 is highly expressed in cancer-associated fibroblasts of esophageal squamous cell carcinoma with a prognostic significance. Oncotarget. 2017; 8(39):65265-65280. PMC: 5630329. DOI: 10.18632/oncotarget.17941. View

12.

Laerm A, Helmbold P, Goldberg M, Dammann R, Holzhausen H, Ballhausen W . Prospero-related homeobox 1 (PROX1) is frequently inactivated by genomic deletions and epigenetic silencing in carcinomas of the bilary system. J Hepatol. 2006; 46(1):89-97. DOI: 10.1016/j.jhep.2006.07.033. View

13.

Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R . Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121(3):335-48. DOI: 10.1016/j.cell.2005.02.034. View

14.

Kim A, Kwak J, Je N, Lee Y, Jung Y . Epithelial-mesenchymal Transition is Associated with Acquired Resistance to 5-Fluorocuracil in HT-29 Colon Cancer Cells. Toxicol Res. 2015; 31(2):151-6. PMC: 4505345. DOI: 10.5487/TR.2015.31.2.151. View

15.

Sung P, Rama N, Imbach J, Fiore S, Ducarouge B, Neves D . Cancer-Associated Fibroblasts Produce Netrin-1 to Control Cancer Cell Plasticity. Cancer Res. 2019; 79(14):3651-3661. DOI: 10.1158/0008-5472.CAN-18-2952. View

16.

Xu L, Lin W, Wen L, Li G . Lgr5 in cancer biology: functional identification of Lgr5 in cancer progression and potential opportunities for novel therapy. Stem Cell Res Ther. 2019; 10(1):219. PMC: 6664754. DOI: 10.1186/s13287-019-1288-8. View

17.

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

18.

Lacina L, Dvorankova B, Smetana Jr K, Chovanec M, Plzak J, Tachezy R . Marker profiling of normal keratinocytes identifies the stroma from squamous cell carcinoma of the oral cavity as a modulatory microenvironment in co-culture. Int J Radiat Biol. 2007; 83(11-12):837-48. DOI: 10.1080/09553000701694343. View

19.

Arneth B . Tumor Microenvironment. Medicina (Kaunas). 2020; 56(1). PMC: 7023392. DOI: 10.3390/medicina56010015. View

20.

Zhou Y, Xia L, Wang H, Oyang L, Su M, Liu Q . Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018; 9(70):33403-33415. PMC: 6161799. DOI: 10.18632/oncotarget.23607. View